TruSpine Technologies PLC Further re: Extension of Subscription Date (6851K)
January 06 2021 - 1:00AM
UK Regulatory
TIDMTSP
RNS Number : 6851K
TruSpine Technologies PLC
06 January 2021
TruSpine Technologies plc
("TruSpine" or the "Company")
Further re: Extension of Subscription Date
TruSpine Technologies plc (AQSE: TSP), the medical device
company focused on the spinal (vertebral) stabilisation market,
announces an update to the announcement released by the Company on
24 December 2020 in which it notified that the subscription funds
of GBP250,000 ("Funds") from Evrensel Capital Partners Limited
("ECP") would be received by 5 January 2021 for the subscription
for 694,444 new ordinary shares in the Company at a price of 36
pence per share.
The Company further advises that the Funds have not been
received by the Company, however the Company and ECP have reached a
further agreement to extend the deadline for the subscription date
to 28 February 2021.
The Company confirms that it is not reliant on these additional
funds for its current working capital requirements.
Ian Roberts, CEO, commented : " Whilst the delay in the
subscription is frustrating, we are in constant communication with
Evrensel Capital Partners Limited. Both the Company and ECP remain
committed to a long-term relationship and feel confident this delay
is only temporary. "
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
The Directors of the Company take responsibility for this
announcement.
Enquiries:
TruSpine Technologies Plc Tel: +44 (0)20 3638 5025
Ian Roberts, CEO
Cairn Financial Advisers LLP (AQSE Corporate Tel: +44 (0)20 7213 0880
Adviser)
Liam Murray / Ludovico Lazzaretti
WH Ireland (Broker) Tel: +44 ( 0)20 7220 1666
Adam Pollock
Walbrook PR (Financial PR Tel: +44 (0) 20 7933 7870 or +44 (0) 7876
& IR) 741 001
Anna Dunphy truspine@walbrookpr.com
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXUVSWRASUARAR
(END) Dow Jones Newswires
January 06, 2021 02:00 ET (07:00 GMT)
TruSpine Technologies (AQSE:TSP)
Historical Stock Chart
From Dec 2024 to Jan 2025
TruSpine Technologies (AQSE:TSP)
Historical Stock Chart
From Jan 2024 to Jan 2025